# CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial

> **Open Intelligence Dossier** · First detected: 2026-09-01 06:07 UTC · Category: Health

## Executive Summary
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial" is generating significant coverage in the Health category, with 1 articles from 1 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Medical Xpress. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Medical Xpress | Best of 2026-08-28 | [Source Link](https://news.google.com/rss/articles/CBMickFVX3lxTFBidU5DVHBRNTVUZnNFcmZUMWo1cDF2ekg4RXYxOThkSnZzZU82Si1ZYXhPNWxuU1dvcElhT09ZdW1ST0NCUzQyTjgtVmJNWUZBZzhCWXFFWFNPSFdndHpwbWpxa184TkhfU1p2RzlaUW5GZ9IBckFVX3lxTFBidU5DVHBRNTVUZnNFcmZUMWo1cDF2ekg4RXYxOThkSnZzZU82Si1ZYXhPNWxuU1dvcElhT09ZdW1ST0NCUzQyTjgtVmJNWUZBZzhCWXFFWFNPSFdndHpwbWpxa184TkhfU1p2RzlaUW5GZw?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-09-01/cd19-car-t-cell-therapy-for-treatment-refractory-seropositive-rheumatoid*